Home
»
Press Room
»
Alopecia Market Size To Reach $100.6 Billion By 2033

Alopecia Market Size To Reach $100.6 Billion By 2033

August 2026 | Report Format: Electronic (PDF)

Alopecia Market Growth & Trends

The global alopecia market size is expected to reach USD 100.6 billion by 2033, registering a CAGR of 8.5% from 2026 to 2033, according to a new report by Grand View Research, Inc. The approval of JAK inhibitors and tyrosine kinase inhibitors along with the rising target disease prevalence is expected to drive market growth.

The prevalence of alopecia areata (AA) and alopecia to talis is increasing globally. It is one of the most commonly encountered problems in clinics in the U.S. As per a research article published in March 2023, in the U.S. and UK, AA accounted for 0.6% to 2% of the new cases encountered in dermatology clinics. In hospital-based studies performed worldwide the incidence of AA is estimated to range between 0.57% to 3.8%.

The approval of new targeted pharmaceutical treatments is a key factor driving the alopecia market growth. For instance, in June 2022, the U.S. FDA approved Lilly’s Olumiant oral tablets for the treatment of severe alopecia in adult patients and is the first systemic treatment approved. Another key drug that is anticipated to be approved in 2023 is Pfizer’s Ritlecitinib. It is a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinases.

Another key factor driving the industry’s growth is the increasing awareness regarding alopecia and thereby increasing treatment rates worldwide. The increase in the level of consciousness regarding physical appearance is one of the major reasons for the rising number of people seeking treatment. Additionally, rising investments in R&D and funding are also fueling market growth.

The limited availability of targeted drugs that treat the underlying condition is one key challenge for the market. While new products with targeted mechanisms of action are being approved the high cost of these drugs in comparison to the already approved products is one of the major hindrances in their widespread adoption.

key Request a free sample copy or view report summary: Alopecia Market Report

Alopecia Market Report Highlights

The androgenetic alopecia segment dominated the alopecia market with the largest revenue share of 70.8% in 2025, owing to its high prevalence across both male and female populations and the increasing demand for long-term hair loss management.
The finasteride & dutasteride segment dominated the alopecia market with the largest revenue share of 26.5% in 2025, due to their established role in the treatment of androgenetic alopecia, the most common form of hair loss worldwide.
The male segment dominated the alopecia market with the largest revenue share of 63.2% in 2025, due to the high prevalence of androgenetic alopecia among men and the strong clinical association between androgen-mediated hair follicle miniaturization and progressive hair loss.
The retail pharmacies segment dominated the alopecia market with the largest revenue share of 50.9% in 2025, due to their established role as the primary distribution channel for prescription and over-the-counter alopecia therapies.